-- BPT567 is the first bifunctional PD1-IL18 immunoconjugate to enter clinical development -- -- Phase 1/2a study will evaluate BPT567...
Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025 Strategic Partnership Discussions Begin for...
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience...
First payment received under Tonix’s contract with the Defense Threat Reduction Agency (DTRA), for up to $34 million over five...
Media Release First safety data anticipated before year end with assessment of PK/PD relationships to follow in H1’CY2025 SYDNEY, AUSTRALIA,...
WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- HMP Partners and The Patel Family LLP, leading investors in innovative healthcare...
Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG...
Avacta Group plc ("Avacta" or "the Group" or "the Company")Avacta Expands its Pipeline with Two Novel Assets Developed Using its...
VALENCIA, Calif. and TEL AVIV, Israel, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of...
• Barrigel™ rectal spacer provides high quality rectal spacing, enabling low dose to the rectum during prostate cancer radiation therapy,...
Planegg/Martinsried, October 17, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on...
STOCKHOLM, SE / ACCESSWIRE / October 17, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR),...
PUBLICATION DEMONSTRATES POTENTIAL FOR multi-marker CTC profiling IN EARLY PROSTATE CANCERParsortix enriched CTCs detected at high rates in localised diseaseMulti-marker...
Color is rolling out its Virtual Cancer Clinic to over 45 employers, health plans, and unions across the country BURLINGAME,...
Peer-reviewed study published in NEJM Catalyst demonstrates Waymark's early intervention model significantly improved clinical outcomes for patients receiving Medicaid in...
HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced...
Paige to participate with PathPresenter at Pathology Visions preconference workshopMONTVILLE, NJ / ACCESSWIRE / October 16, 2024 / PathPresenter, a...
PH-894: Potent and Specific Silencing of BRD4 in NK CellsMarlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp....
Gelclair® is the company's third commercialized prescription productOral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous...
MIAMI, FL, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...